Aug 28, 2024 / 11:00AM GMT
Martin Amark - Xbrane Biopharma AB - Chief Executive Officer
Hello, and welcome to the webcast today in relation to the second quarter 2024 financial report of Xbrane Biopharma. My name is Martin, I'm the CEO, and I have also our CFO, Anette Lindqvist, with me today. We will go through a brief presentation highlighting the operational advances during the past quarter and also the financials. And we will take questions thereafter, and you can ask questions, both via audio and also via the chat, and we'll do our best to answer to them.
So let's start off here. Most of those of you who are calling in probably know what we are engaged in. We are a biosimilar developer. So we're developing follow-on drugs to approved biologics, which can be launched post patent expiration or loss of exclusivity after respective originated products. Our portfolio consists of 4 biosimilars and biosimilar candidates.
First one, Ximluci, approved biosimilar to Lucentis in Europe and launched since first quarter 2023, by our commercialization partner, STADA. We are going through a regulatory process with FDA for a
Q2 2024 Xbrane Biopharma AB Earnings Call Transcript
Aug 28, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers